$TECX News

Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - Slideshow

UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare

Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case

Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93

Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients

Raymond James Upgrades Tectonic Therapeutic to Strong Buy, Raises Price Target to $81

TECTONIC THERAPEUTIC INC (NASDAQ:TECX) Q1 Loss Wider Than Expected, Pipeline Progress Provides Key Catalyst

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Q1 EPS $(1.34) Misses $(1.18) Estimate

Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Stifel Initiates Coverage On Tectonic Therapeutic with Buy Rating, Announces Price Target of $75

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic to Participate in March Investor Conferences

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights